8-K Announcements
6Material company update
May 4, 2026·SEC
Material company update
Mar 19, 2026·SEC
Material company update
Feb 9, 2026·SEC
Marker Therapeutics, Inc.(MRKR)Earnings, Financials & Key Ratios
MRKR•NASDAQ
Price updated Jun 19, 2026
AboutMarker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells expressing tumor-associated antigens. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, and various solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; and off-the-shelf products in various indications. It is also developing TPIV100/110, a peptide-based immunotherapeutic vaccines for the treatment of breast and ovarian cancer cells; and TPIV200, which is in Phase 2 clinical trial for the treatment of breast and ovarian cancers. The company was founded in 1999 and is headquartered in Houston, Texas.Show more
- Revenue$0-100.0%
- EBITDA-$12M-11.9%
- Net Income-$12M-13.3%
- EPS (Diluted)-0.79+33.6%
- ROE-0%+100.0%
MRKR Key Insights
Marker Therapeutics, Inc. (MRKR) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y profit CAGR of 15.8%
- ✓High quality earnings: Operating CF exceeds net income
✗Weaknesses
- ✗Weak Piotroski F-Score: 2/9
- ✗Shares diluted 70.5% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when MRKR posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
MRKR Price & Volume
Marker Therapeutics, Inc. (MRKR) stock price & volume — 10-year historical chart
Loading chart...
MRKR Growth Metrics
Marker Therapeutics, Inc. (MRKR) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-63.24%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM14.77%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM49.62%
Return on Capital
10 Years-122.53%
5 Years-54.36%
3 Years-46.62%
Last Year-0%
MRKR Recent Earnings
Marker Therapeutics, Inc. (MRKR) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 10/12 qtrs (83%)●Beat Revenue 6/12 qtrs (100%)
Q2 2026Latest
May 15, 2026Metric
Actual
Est
EPS
$0.16+11.1%
$0.18
Rev
—
$682,100
Q2 2026
Mar 18, 2026Metric
Actual
Est
EPS
$0.04+81.0%
$0.21
Rev
$1M+61.3%
$682,100
Q4 2025
Nov 13, 2025Metric
Actual
Est
EPS
$0.12+66.7%
$0.36
Rev
$1M+70.5%
$723,000
Q3 2025
Aug 14, 2025Metric
Actual
Est
EPS
$0.29+4.6%
$0.30
Rev
$861,184+100.0%
$430,600
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 15, 2026 | $0.16vs $0.18+11.1% | —vs $682,100 |
| Q2 2026 | Mar 18, 2026 | $0.04vs $0.21+81.0% | $1Mvs $682,100+61.3% |
| Q4 2025 | Nov 13, 2025 | $0.12vs $0.36+66.7% | $1Mvs $723,000+70.5% |
| Q3 2025 | Aug 14, 2025 | $0.29vs $0.30+4.6% | $861,184vs $430,600+100.0% |
Based on last 12 quarters of dataView full earnings history →
MRKR Peer Comparison
Marker Therapeutics, Inc. (MRKR) competitors in Cell and Gene Therapy Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 FATE | 243.61M | 2.09 | -1.82 | -51.24% | -20.57% | -58.89% | 0.38 | |
 AGEN | 124.93M | 3.00 | -882.35 | 10.37% | 52.16% | |||
 ADCT | 138.64M | 1.09 | -0.97 | 14.85% | -173.02% | |||
 IMVT | 7.26B | 35.34 | -12.76 | -68.16% | 0.00 | |||
 CABA | 463.08M | 2.84 | -1.73 | -131.58% | 0.24 | |||
 KYMR | 7.38B | 90.43 | -24.51 | -16.72% | -6.12% | -25.02% | 0.05 | |
 ALKT | 1.57B | 14.68 | -31.91 | 32.89% | -10.55% | -13.96% | 0.98 | |
 NKTR | 1.19B | 60.98 | -6.27 | -43.89% | -284.18% | -87% | 1.66 |
Compare MRKR vs Peers
Marker Therapeutics, Inc. (MRKR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
MRKR Income Statement
Marker Therapeutics, Inc. (MRKR) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 183.06K | 205.99K | 213.19K | 466.79K | 1.24M | 3.51M | 3.31M | 6.59M | 0 | 2.09M |
Revenue Growth % | - | 12.53% | 3.5% | 118.95% | 166.01% | 182.96% | -5.76% | 99.06% | -100% | -63.24% |
Cost of Goods Sold | 5.25M | 124M | 12.76M | 18.88M | 3.16M | 11.97M | 10.42M | 13.47M | 0 | 4.18M |
COGS % of Revenue | 2868.4% | 60194.96% | 5987.41% | 4044.9% | 254.7% | 340.64% | 314.6% | 204.33% | - | - |
Gross Profit | -5.07M▲ 0% | -123.79M▼ 2342.6% | -12.55M▲ 89.9% | -18.41M▼ 46.7% | -1.92M▲ 89.6% | -8.45M▼ 340.1% | -7.11M▲ 16.0% | -6.88M▲ 3.2% | 0▲ 100.0% | -2.08M▲ 0% |
Gross Margin % | -2768.43% | -60094.95% | -5887.41% | -3944.86% | -154.7% | -240.64% | -214.6% | -104.33% | - | -99.47% |
Gross Profit Growth % | - | -2342.62% | 89.86% | -46.71% | 89.57% | -340.15% | 15.96% | 3.22% | 100% | - |
Operating Expenses | 6.41M | 148.38M | 9.98M | 10.47M | 37.56M | 11.34M | 7.48M | 4.24M | 12.89M | 10.27M |
OpEx % of Revenue | 3502.6% | 72030.25% | 4679.87% | 2243.43% | 3024.62% | 322.64% | 225.78% | 64.35% | - | - |
Selling, General & Admin | 6.41M | 24.38M | 9.98M | 10.47M | 9.76M | 11.34M | 7.48M | 4.24M | 4.18M | 4.05M |
SG&A % of Revenue | 3502.6% | 11835.3% | 4679.87% | 2243.43% | 786.19% | 322.64% | 225.78% | 64.35% | - | - |
Research & Development | 5.25M | 124M | 12.76M | 18.88M | 27.79M | 11.97M | 10.42M | 13.47M | 11.8M | 11.51M |
R&D % of Revenue | 2868.4% | 60194.96% | 5987.41% | 4044.9% | 2238.44% | 340.64% | 314.6% | 204.33% | - | - |
Other Operating Expenses | -183K | 116.05M | -12.76M | -18.88M | 0 | -11.97M | -10.42M | -13.47M | -3.09M | -2M |
Operating Income | -11.48M▲ 0% | -148.17M▼ 1190.7% | -22.53M▲ 84.8% | -28.89M▼ 28.2% | -39.48M▼ 36.7% | -19.79M▲ 49.9% | -14.58M▲ 26.3% | -11.12M▲ 23.7% | -12.89M▼ 15.9% | -12.35M▲ 0% |
Operating Margin % | -6271.03% | -71930.25% | -10567.28% | -6188.29% | -3179.32% | -563.28% | -440.37% | -168.69% | - | -589.95% |
Operating Income Growth % | -35.19% | -1190.7% | 84.8% | -28.22% | -36.67% | 49.87% | 26.32% | 23.75% | -15.94% | - |
EBITDA | 0 | 0 | -22.42M | -27.81M | -36.32M | -17M | -11.79M | -11.12M | -12.44M | -12.35M |
EBITDA Margin % | - | - | -10517.97% | -5957.78% | -2924.62% | -483.9% | -356.14% | -168.69% | - | -589.95% |
EBITDA Growth % | - | - | - | -24.02% | -30.58% | 53.18% | 30.64% | 5.71% | -11.86% | -83.99% |
D&A (Non-Cash Add-back) | 11.48M | 148.17M | 105.12K | 1.08M | 3.16M | 2.79M | 2.79M | 2 | 0 | -1 |
EBIT | -11.3M | -147.97M | -22.53M | -28.71M | -41.88M | -19.79M | -14.58M | -11.12M | -12.44M | -12.22M |
Net Interest Income | 0 | 253.72K | 1.08M | 148.74K | 5.7K | 248.06K | 539.16K | 437.01K | 594.21K | 564.61K |
Interest Income | 0 | 253.72K | 1.08M | 148.74K | 5.7K | 248.06K | 539.16K | 437.01K | 594.21K | 564.61K |
Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Income/Expense | 497.87K | 213.72K | 1.1M | 179.74K | -2.4M | 15.09K | 539.16K | 437.01K | 711.65K | 1.44M |
Pretax Income | -10.98M▲ 0% | -147.96M▼ 1247.3% | -21.43M▲ 85.5% | -28.71M▼ 34.0% | -41.88M▼ 45.9% | -19.78M▲ 52.8% | -14.04M▲ 29.0% | -10.68M▲ 23.9% | -12.18M▼ 14.0% | -10.91M▲ 0% |
Pretax Margin % | -5998.99% | -71826.36% | -10050.92% | -6149.73% | -3372.68% | -562.85% | -424.09% | -162.06% | - | -521.07% |
Income Tax | 0 | -214K | 0 | 0 | 0 | 0 | 3.67K | 49.95K | -15.16K | -15.16K |
Effective Tax Rate % | 0% | 0.14% | 0% | 0% | 0% | 0% | -0.03% | -0.47% | 0.12% | 0.14% |
Net Income | -10.98M▲ 0% | -147.96M▼ 1247.3% | -21.43M▲ 85.5% | -28.71M▼ 34.0% | -41.88M▼ 45.9% | -29.93M▲ 28.5% | -8.24M▲ 72.5% | -10.73M▼ 30.3% | -12.16M▼ 13.3% | -10.9M▲ 0% |
Net Margin % | -5998.99% | -71826.36% | -10050.92% | -6149.73% | -3372.68% | -851.87% | -248.76% | -162.82% | - | -520.35% |
Net Income Growth % | -347.33% | -1247.28% | 85.52% | -33.97% | -45.89% | 28.53% | 72.48% | -30.28% | -13.35% | 14.77% |
Net Income (Continuing) | -10.98M | -147.96M | -21.43M | -28.71M | -41.88M | -19.78M | -14.05M | -10.73M | -12.16M | -10.9M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | -10.15M | 5.81M | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -11.62▲ 0% | -77.50▼ 567.0% | -4.70▲ 93.9% | -6.10▼ 29.8% | -5.47▲ 10.3% | -3.58▲ 34.6% | -1.93▲ 46.1% | -1.19▲ 38.3% | -0.79▲ 33.6% | -0.56▲ 0% |
EPS Growth % | -251.06% | -566.95% | 93.94% | -29.79% | 10.33% | 34.55% | 46.09% | 38.34% | 33.61% | 49.62% |
EPS (Basic) | -11.62 | -77.50 | -4.70 | -6.10 | -5.47 | -3.58 | -1.93 | -1.19 | -0.79 | - |
Diluted Shares Outstanding | 945.35K | 1.91M | 4.56M | 4.7M | 7.65M | 8.35M | 8.81M | 8.98M | 15.31M | 19.31M |
Basic Shares Outstanding | 945.35K | 1.91M | 4.56M | 4.7M | 7.65M | 8.35M | 8.81M | 8.98M | 15.31M | 19.31M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
MRKR Balance Sheet
Marker Therapeutics, Inc. (MRKR) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 5.18M | 62M | 45.49M | 24.41M | 45.98M | 16.62M | 17.13M | 22.02M | 19.07T | 17.43M |
Cash & Short-Term Investments | 5.13M | 61.75M | 43.9M | 21.35M | 42.35M | 11.78M | 15.11M | 19.19M | 16.07T | 14.92M |
Cash Only | 5.13M | 61.75M | 43.9M | 21.35M | 42.35M | 11.78M | 15.11M | 19.19M | 16.07T | 14.92M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 0 | 108.18K | 56.19K | 1M | 237 | 2.4M | 1.03M | 2.35M | 1.37M | 1.38M |
Days Sales Outstanding | - | 191.68 | 96.2 | 782.38 | 0.07 | 249.53 | 113.3 | 129.96 | - | 265.18 |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | -988.13K | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
Other Current Assets | 0 | 141.72K | 1.53M | 0 | 1.15M | 585.84K | 988.13K | 0 | 3T | 1.14M |
Total Non-Current Assets | 0 | 148K | 872.7K | 21.2M | 22.15M | 17.8M | 0 | 0 | 0 | 0 |
Property, Plant & Equipment | 0 | 148K | 872.7K | 21.2M | 22.15M | 17.8M | 0 | 0 | 0 | 0 |
Fixed Asset Turnover | - | 1.39x | 0.24x | 0.02x | 0.06x | 0.20x | - | - | - | - |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 | 143 | 0 | 0 | 0 | 0 |
Total Assets | 5.18M▲ 0% | 62.14M▲ 1099.6% | 46.36M▼ 25.4% | 45.61M▼ 1.6% | 68.14M▲ 49.4% | 34.42M▼ 49.5% | 17.13M▼ 50.2% | 22.02M▲ 28.6% | 19.07T▲ 86596268.5% | 17.43M▲ 0% |
Asset Turnover | 0.04x | 0.00x | 0.00x | 0.01x | 0.02x | 0.10x | 0.19x | 0.30x | - | 0.00x |
Asset Growth % | -34.6% | 1099.6% | -25.4% | -1.61% | 49.37% | -49.48% | -50.24% | 28.58% | 86596268.5% | 86596396.8% |
Total Current Liabilities | 1.52M | 2.8M | 1.99M | 6.4M | 12.9M | 7.78M | 3.07M | 3.46M | 2.27T | 3.64M |
Accounts Payable | 1.01M | 1.62M | 993K | 2.94M | 5.14M | 1.1M | 961K | 1.07M | 793.73K | 1.5M |
Days Payables Outstanding | 70.55 | 4.77 | 28.39 | 56.74 | 593.67 | 33.58 | 33.67 | 28.89 | - | 108.35 |
Short-Term Debt | 5K | 0 | 204.13K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Deferred Revenue (Current) | 493K | 0 | 0 | 0 | 1.15M | 2.5M | 0 | 0 | 974.8B | 974.8B |
Other Current Liabilities | 166.31K | 465.57K | 472.68K | 1.69M | 2.05M | 2.93M | 1.84M | 86.95K | 1.3T | 1.36M |
Current Ratio | 3.40x | 22.11x | 22.83x | 3.81x | 3.56x | 2.14x | 5.57x | 6.36x | 8.39x | 4.79x |
Quick Ratio | 3.40x | 22.11x | 22.83x | 3.81x | 3.56x | 2.14x | 5.89x | 6.36x | 8.39x | 4.79x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | 156.83 |
Total Non-Current Liabilities | 1.02M | 1.62M | 280.25K | 11.87M | 11.25M | 7.04M | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 0 | 0 | 280.25K | 11.87M | 11.25M | 7.04M | 0 | 0 | 0 | 0 |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 1.52M | 2.8M | 2.27M | 18.27M | 24.15M | 14.82M | 3.07M | 3.46M | 2.27T | 3.64M |
Total Debt | 5K | 0 | 484.38K | 12.26M | 11.87M | 7.62M | 0 | 0 | 0 | 0 |
Net Debt | -5.12M | -61.75M | -43.42M | -9.1M | -30.48M | -4.17M | -15.11M | -19.19M | -16.07T | -14.92M |
Debt / Equity | 0.00x | - | 0.01x | 0.45x | 0.27x | 0.39x | - | - | - | 0.00x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.00x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 1.21x |
Interest Coverage | - | - | - | - | - | - | - | - | - | - |
Total Equity | 3.66M▲ 0% | 59.34M▲ 1522.2% | 44.09M▼ 25.7% | 27.34M▼ 38.0% | 43.99M▲ 60.9% | 19.6M▼ 55.4% | 14.05M▼ 28.3% | 18.56M▲ 32.1% | 16.8T▲ 90507748.6% | 13.8M▲ 0% |
Equity Growth % | -40.85% | 1522.16% | -25.71% | -37.97% | 60.86% | -55.44% | -28.31% | 32.06% | 90507748.57% | 90507898.73% |
Book Value per Share | 3.87 | 31.08 | 9.67 | 5.81 | 5.75 | 2.35 | 1.60 | 2.07 | 999999.00 | 0.71 |
Total Shareholders' Equity | 3.66M | 59.34M | 44.09M | 27.34M | 43.99M | 19.6M | 14.05M | 18.56M | 16.8T | 13.8M |
Common Stock | 10.62K | 45.44K | 45.73K | 50.73K | 8.31K | 8.41K | 8.89K | 10.71K | 16.67B | 16.67K |
Retained Earnings | -157.42M | -306.11M | -327.53M | -356.24M | -398.12M | -428.05M | -436.29M | -447.02M | -459.18T | -462.36M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
MRKR Cash Flow Statement
Marker Therapeutics, Inc. (MRKR) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -8.44M | -14.48M | -18.28M | -20.03M | -27.28M | -26.97M | -16.44M | -10.91M | -12.01T | -7.92M |
Operating CF Margin % | -4610.1% | -7029.29% | -8576.36% | -4292.06% | -2196.95% | -767.66% | -496.51% | -165.53% | - | - |
Operating CF Growth % | -29.64% | -71.57% | -26.27% | -9.57% | -36.16% | 1.13% | 39.05% | 33.64% | -99999900% | -147.05% |
Net Income | -10.98M | -147.96M | -21.43M | -28.71M | -41.88M | -19.78M | -14.05M | -10.73M | -12.16T | -10.9M |
Depreciation & Amortization | 0 | 0 | 286.58K | 1.08M | 3.16M | 0 | 0 | 0 | 0 | 0 |
Stock-Based Compensation | 2.74M | 16.35M | 5.36M | 5.23M | 5.96M | 0 | 858.27K | 245.86K | 537.54B | 158.4K |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | -497.87K | 116.08M | -18K | -31K | 0 | -2.43M | -6.1M | 0 | -388B | 178.42K |
Working Capital Changes | 302.37K | 1.04M | -2.48M | 2.4M | 5.47M | -4.76M | 2.85M | -424.87K | -388K | 2.64M |
Change in Receivables | 0 | 0 | 51.99K | 55.63K | 1M | -2.4M | 1.37M | -1.32M | 977.3K | 1.08M |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 283.37K | 1.24M | -963.97K | 0 | 0 | -1.32M | 611.26K | 8.76K | -454.57K | -176.38K |
Cash from Investing | 0 | -147.67K | -374.98K | -9.25M | -3.13M | -4.95M | 18.66M | 0 | 0 | 0 |
Capital Expenditures | 0 | -147.67K | -374.98K | -9.25M | -3.13M | 0 | 0 | 0 | 0 | 0 |
CapEx % of Revenue | - | 71.69% | 175.89% | 1982.26% | 252.16% | 0% | - | - | - | 0% |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | 0 | 0 | -4.95M | 18.66M | 0 | 0 | 0 |
Cash from Financing | 5.72M | 71.25M | 816.48K | 6.74M | 52.56M | 202.13K | 1.11M | 14.99M | 9.86T | 9.86M |
Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 5.1M | 66.87M | 816.48K | 6.19M | 52.55M | 202.13K | 1.01M | 14.93M | 9.86M | 9.86M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | -310.49K | -71.71K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 619.62K | 4.37M | 0 | 550K | 3.09K | 0 | 90.48K | 62.16K | 9.86T | 0 |
Net Change in Cash | -2.72M▲ 0% | 56.62M▲ 2180.0% | -17.84M▼ 131.5% | -22.55M▼ 26.4% | 22.14M▲ 198.2% | -31.72M▼ 243.2% | 3.33M▲ 110.5% | 4.08M▲ 22.6% | -2.15T▼ 52673421.9% | 1.95M▲ 0% |
Free Cash Flow | -8.44M▲ 0% | -14.63M▼ 73.3% | -18.66M▼ 27.6% | -29.29M▼ 57.0% | -30.41M▼ 3.8% | -26.97M▲ 11.3% | -16.44M▲ 39.0% | -10.91M▲ 33.6% | -12.01T▼ 110116529.0% | -7.92M▲ 0% |
FCF Margin % | -4610.1% | -7100.98% | -8752.25% | -6274.32% | -2449.11% | -767.66% | -496.51% | -165.53% | - | -378.13% |
FCF Growth % | -29.64% | -73.32% | -27.56% | -56.96% | -3.84% | 11.31% | 39.05% | 33.64% | -99999900% | 37.02% |
FCF per Share | -8.93 | -7.66 | -4.09 | -6.23 | -3.97 | -3.23 | -1.87 | -1.21 | -784721.16 | -0.41 |
FCF Conversion (FCF/Net Income) | 0.77x | 0.10x | 0.85x | 0.70x | 0.65x | 0.90x | 2.00x | 1.02x | 987706.04x | 0.73x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
MRKR Key Ratios
Marker Therapeutics, Inc. (MRKR) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -223.15% | -469.72% | -41.44% | -80.37% | -117.42% | -94.14% | -48.95% | -65.81% | -0% | -0% |
Return on Invested Capital (ROIC) | - | - | - | -229.06% | -186.5% | -102.59% | -152.14% | - | -0% | -0.01% |
Gross Margin | -2768.43% | -60094.95% | -5887.41% | -3944.86% | -154.7% | -240.64% | -214.6% | -104.33% | - | -99.47% |
Net Margin | -5998.99% | -71826.36% | -10050.92% | -6149.73% | -3372.68% | -851.87% | -248.76% | -162.82% | - | -520.35% |
Debt / Equity | 0.00x | - | 0.01x | 0.45x | 0.27x | 0.39x | - | - | - | 0.00x |
FCF Conversion | 0.77x | 0.10x | 0.85x | 0.70x | 0.65x | 0.90x | 2.00x | 1.02x | 987706.04x | 0.73x |
Revenue Growth | - | 12.53% | 3.5% | 118.95% | 166.01% | 182.96% | -5.76% | 99.06% | -100% | -63.24% |
Related:MRKR Dividend History·MRKR Revenue History·MRKR Price History·MRKR P/E History·MRKR Financial Ratios·MRKR Institutional Holders
MRKR SEC Filings & Documents
Marker Therapeutics, Inc. (MRKR) SEC filings — annual & quarterly reports (10-K, 10-Q)
MRKR Frequently Asked Questions
Marker Therapeutics, Inc. (MRKR) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Marker Therapeutics, Inc. (MRKR) reported $2.1M in revenue for fiscal year 2025. This represents a 1635% increase from $0.1M in 1999.
Marker Therapeutics, Inc. (MRKR) saw revenue decline by 100.0% over the past year.
Marker Therapeutics, Inc. (MRKR) reported a net loss of $10.9M for fiscal year 2025.
Dividend & Returns
Marker Therapeutics, Inc. (MRKR) has a return on equity (ROE) of -0.0%. Negative ROE indicates the company is unprofitable.
Marker Therapeutics, Inc. (MRKR) had negative free cash flow of $7.9M in fiscal year 2025, likely due to heavy capital investments.